Published in Lab Invest on July 01, 1980
Ocular tropism of respiratory viruses. Microbiol Mol Biol Rev (2013) 0.84
New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol (1983) 26.67
Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol (2001) 24.36
Recovery of herpes-simplex virus from human trigeminal ganglions. N Engl J Med (1973) 5.66
Exacerbations of multiple sclerosis in patients treated with gamma interferon. Lancet (1987) 3.79
Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology (1987) 3.11
Slow virus replication: the role of macrophages in the persistence and expression of visna viruses of sheep and goats. J Gen Virol (1982) 2.87
Prevalence and types of dementia in the very old: results from the Canadian Study of Health and Aging. Neurology (1994) 2.10
Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol (2007) 1.83
Neurotoxic effects of cisplatin therapy. Arch Neurol (1982) 1.83
H reflex studies in cerebral palsy patients undergoing partial dorsal rhizotomy. Muscle Nerve (1994) 1.83
Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. AJNR Am J Neuroradiol (2006) 1.78
Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology (2001) 1.76
Hydrocephalus following viral infection: the pathology of aqueductal stenosis developing after experimental mumps virus infection. J Neuropathol Exp Neurol (1968) 1.75
Hydrocephalus as a sequela of experimental myxovirus infections. Exp Mol Pathol (1969) 1.68
Diagnosis of rabies by immunofluorescence in trypsin-treated histologic sections. JAMA (1980) 1.67
Cognitive impairment in the nondemented elderly. Results from the Canadian Study of Health and Aging. Arch Neurol (1995) 1.66
Herpes zoster ophthalmicus and delayed contralateral hemiparesis caused by cerebral angiitis: diagnosis and management approaches. Ann Neurol (1983) 1.60
Variable results after rituximab in neuromyelitis optica. J Neurol Sci (2012) 1.58
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Linomide in relapsing and secondary progressive MS: part I: trial design and clinical results. North American Linomide Investigators. Neurology (2000) 1.52
Five measles virus antigens demonstrated by use of mouse hybridoma antibodies in productively infected tissue culture cells. Arch Virol (1982) 1.50
Measles encephalomyelitis--clinical and immunologic studies. N Engl J Med (1984) 1.50
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Copolymer 1: a most reasonable alternative therapy for early relapsing-remitting multiple sclerosis with mild disability. Neurology (1995) 1.48
Isolation of a Streptococcus mutans strain producing a novel bacteriocin. Infect Immun (1984) 1.48
Enhancement of fluorescent antibody staining of viral antigens in formalin-fixed tissues by trypsin digestion. J Infect Dis (1979) 1.46
Acquired toxoplasmosis. A neglected cause of treatable nervous system disease. Arch Neurol (1975) 1.44
Immunochemical identification of rubella virus hemagglutinin. Virology (1983) 1.44
Experimental subacute sclerosing panencephalitis in the hamster: correlation of age with chronic inclusion-cell encephalitis. J Infect Dis (1972) 1.41
Relationship of urinary myelin basic protein-like material with cranial magnetic resonance imaging in advanced multiple sclerosis. Arch Neurol (2001) 1.40
3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler (2008) 1.39
The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (1999) 1.38
Sequence determination of the mumps virus HN gene. Virology (1988) 1.38
Effects of seasons on magnetic resonance imaging--measured disease activity in patients with multiple sclerosis. Ann Neurol (2001) 1.35
Systemic alpha-interferon therapy of multiple sclerosis. Neurology (1984) 1.35
Pathophysiology of multiple sclerosis and the place of teriflunomide. Acta Neurol Scand (2010) 1.34
Neutralizing antibody spectrum determines the antigenic profiles of emerging mutants of visna virus. Infect Immun (1981) 1.31
The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. Neurology (1999) 1.31
Primary culture of capillary endothelium from rat brain. In Vitro (1981) 1.30
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Conversion of nonfusing mumps virus infections to fusing infections by selective proteolysis of the HN glycoprotein. Virology (1983) 1.28
Progressive rubella panencephalitis. Late onset after congenital rubella. N Engl J Med (1975) 1.28
Biochemical features of mumps virus neuraminidases and their relationship with pathogenicity. Virology (1981) 1.27
Detailed immunologic analysis of the structural polypeptides of rubella virus using monoclonal antibodies. Virology (1985) 1.26
Neuronal and oligodendroglial infection by the WW strain of Theiler's virus. Lab Invest (1979) 1.25
A dual approach for minimizing false lesion classifications on magnetic resonance images. Magn Reson Med (1997) 1.24
Virus-induced hydrocephalus: development of aqueductal stenosis in hamsters after mumps infection. Science (1967) 1.24
Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler (2000) 1.23
Tubular aggregates in endoplasmic reticulum: evidence against their viral nature. J Ultrastruct Res (1972) 1.23
Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis. J Virol (1985) 1.23
Diaphragmatic paralysis in motor neuron disease. Report of two cases and a review of the literature. Neurology (1978) 1.22
Cloning and sequencing of the mumps virus fusion protein gene. Virology (1987) 1.20
Phylogenetic analysis of partial sequences of elongation factor 1alpha identifies major groups of lice (Insecta: Phthiraptera). Mol Phylogenet Evol (2001) 1.20
A fusing mumps virus variant selected from a nonfusing parent with the neuraminidase inhibitor 2-deoxy-2,3-dehydro-N-acetylneuraminic acid. Virology (1986) 1.18
Virus-specific intracytoplasmic inclusions in mouse brain produced by a newly isolated strain of Theiler virus. I. Virologic and morphologic studies. Lab Invest (1977) 1.18
Progressive multifocal leukoencephalopathy and cytarabine. Remission with treatment. JAMA (1973) 1.17
Isolation of metabolically active capillaries from rat brain. J Neurochem (1975) 1.15
A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients. Mult Scler (2006) 1.15
Primary degenerative dementia without Alzheimer pathology. Can J Neurol Sci (1986) 1.13
Determinants of overall quality of life in secondary progressive MS: a longitudinal study. Neurology (2001) 1.13
Postinfectious leukoencephalitis complicating Mycoplasma pneumoniae infection. Arch Neurol (1983) 1.12
Adenine arabinoside in the treatment of progressive multifocal leukoencephalopathy: use of virus-containing cells in the urine to assess response to therapy. Ann Neurol (1977) 1.10
Measurement error of two different techniques for brain atrophy assessment in multiple sclerosis. Neurology (2004) 1.09
United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center. Mult Scler (2001) 1.09
Short-term brain volume change in relapsing-remitting multiple sclerosis: effect of glatiramer acetate and implications. Brain (2001) 1.08
Agarose electrophoresis of cerebrospinal fluid in multiple sclerosis. A simplified method for demonstrating cerebrospinal fluid oligoclonal immunoglobulin bands. Neurology (1977) 1.08
Putting magnetic resonance spectroscopy studies in context: axonal damage and disability in multiple sclerosis. Semin Neurol (1998) 1.08
Mouse cytomegalovirus: placental infection. J Infect Dis (1969) 1.07
The clinical and pathological spectrum of brain-stem vascular malformations. Long-term course stimulates multiple sclerosis. Arch Neurol (1980) 1.07
Aqueductal stenosis and hydrocephalus after mumps encephalitis. N Engl J Med (1970) 1.06
Persistent herpes simplex virus infection in rabbit trigeminal ganglia. Lab Invest (1974) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Systemic recombinant alpha-2 interferon therapy in relapsing multiple sclerosis. Arch Neurol (1986) 1.04
Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol (1998) 1.04
Viral antibodies in cerebrospinal fluid of multiple sclerosis and control patients: comparison between radioimmunoassay and conventional techniques. J Clin Microbiol (1978) 1.04
Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J Clin Immunol (1985) 1.04
The diagnosis of Huntington's disease. Neurology (1986) 1.04
Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler (2008) 1.04
Prognosis of the individual course of disease--steps in developing a decision support tool for Multiple Sclerosis. BMC Med Inform Decis Mak (2007) 1.04
Comprehensive viral immunology of multiple sclerosis. III. Analysis of CSF antibodies by radioimmunoassay. Arch Neurol (1980) 1.04
Ultrastructure of mumps virus replication in newborn hamster central nervous system. Lab Invest (1974) 1.04
The neuropathology of progressive rubella panencephalitis of late onset. Brain (1976) 1.04
Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology (1996) 1.04
Grey matter abnormalities in multiple sclerosis: proton magnetic resonance spectroscopic imaging. Mult Scler (2001) 1.02
Characterization of immune complexes in progressive rubella panencephalitis. Ann Neurol (1981) 1.02
Colonization of the human oral cavity by a strain of Streptococcus mutans. J Dent Res (1985) 1.02
A model of the structural organization of rubella virions. Rev Infect Dis (1985) 1.01
Granular ependymitis. Occurrence in myxovirus infected rodents and prevalence in man. Am J Pathol (1972) 1.01
Intracellular maturation of mumps virus hemagglutinin-neuraminidase glycoprotein: conformational changes detected with monoclonal antibodies. J Virol (1986) 0.99
Differentiation of mumps virus strains with monoclonal antibody to the HN glycoprotein. Infect Immun (1982) 0.98
Virulence and persistence of three prototype strains of mumps virus in newborn hamsters. Arch Virol (1978) 0.98
Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Ann Neurol (1998) 0.98
Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial. Neurology (1996) 0.98
CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis. Arch Neurol (1980) 0.98